Sindu Iska, MD

49 posts

Sindu Iska, MD banner
Sindu Iska, MD

Sindu Iska, MD

@IskaSindu

Heme/onc fellow @MCG_AUG 🇮🇳🇺🇸

Augusta, GA Katılım Eylül 2015
824 Takip Edilen339 Takipçiler
Sindu Iska, MD retweetledi
Jorge Cortes MD
Jorge Cortes MD@jorgecortesmd·
I enjoyed a great conversation with @OncBrothers about management of CML. @GACancerCenter @icmlf x.com/oncbrothers/st…
Oncology Brothers@OncBrothers

#Hematology: w/ @GCC_Cortes we 🗣️ the current SoC/landscape for #CML (1st, 2nd, and 3rd Gen TKIs) Full discussion: ⭐️ cancernetwork.com/treatment-algo… ⭐️ oncbrothers.com/cml-2024 ⭐️ Also on the “Oncology Brothers” podcast #HemeTwitter #MedTwitter #OncTwitter @CancerNetwrk #leusm

English
1
6
26
3.1K
Sindu Iska, MD retweetledi
Vincent Rajkumar
Vincent Rajkumar@VincentRK·
Updated Active Drugs in myeloma with mechanism of action in one slide. FDA Approved drugs: Black font Investigational: Blue font #MyelomaVR
Vincent Rajkumar tweet media
English
4
50
160
37.1K
Sindu Iska, MD retweetledi
JAMA Oncology
JAMA Oncology@JAMAOnc·
The 10-year interval between colonoscopy screenings for colorectal cancer (CRC) could be extended to 15 years in patients with no family history of CRC and negative findings on their first colonoscopy, finds matched cohort study. ja.ma/3yiIYqZ
JAMA Oncology tweet media
English
0
20
39
4.8K
Saad Sabbagh
Saad Sabbagh@SaadMSabbagh·
Excited to share our latest publication in @JAMANetworkOpen on biomarker testing disparities in metastatic colorectal cancer. Honored to work with the incredible team, mentors, and collaborators at @Cancer_CCFla @CleveClinicFL @drznahleh @ArunNagarajanMD @SWexner
JAMA Network Open@JAMANetworkOpen

In a national cohort of patients with metastatic colorectal cancer, older age, lower educational level, community-setting treatment, South-Central US divisions, and rural areas of residence were associated with decreased MSI and KRAS testing. ja.ma/4cLWaDu

English
11
7
64
9.6K
Thejus Jayakrishnan
Thejus Jayakrishnan@ThejusJay·
It was an honor to receive the fellowship diploma from one of the best oncologists and role models I have worked with! Thank you, @smitha42
Thejus Jayakrishnan tweet media
English
14
1
53
3.9K
Sindu Iska, MD
Sindu Iska, MD@IskaSindu·
@HemOncFellows Thank you for doing this for us! How can we be efficient during fellowship ? Balancing training ,clinical updates, research and life in general. Appreciate your suggestions !
English
1
0
3
224
Sindu Iska, MD retweetledi
Vincent Rajkumar
Vincent Rajkumar@VincentRK·
In one year since this thread, we have 3 more new drugs approved for myeloma: teclistamab, elranatamab, and talquetamab. Amazing progress.
Vincent Rajkumar@VincentRK

My slides and key takeaways from 2 days of intense discussion at the FDA/IMS meeting on drug development in myeloma. Applies to other cancers as well. #MedTwitter @FDAOncology @Myeloma_Society 1) 15 new drugs approved for myeloma in the last 20 years! Incredible.

English
3
15
73
17.5K
Tulsi Jose, MD
Tulsi Jose, MD@drtulsijose·
We all have that one "special" friend in our lives that can uplift us through anything. The evening before #match2024 fellowship results came out, I had to pick up & call @ShriyaDr. Our friendship had blossomed to #sisterhood & this beautiful suprise was in the mail waiting. ❤️
Tulsi Jose, MD tweet media
English
1
1
10
1.8K
Asmita Shukla
Asmita Shukla@AsmitaShukla01·
Look who I met last week at ASH. My very first friend in the US. Have lots of memories from 2018/2019!
Asmita Shukla tweet media
English
1
0
2
178
Sindu Iska, MD
Sindu Iska, MD@IskaSindu·
@PamChMD Thank you Pam 😊 that’s really sweet of you !
San Diego, CA 🇺🇸 English
0
0
2
36

Keşfet

@FDAOncology @OncBrothers @GACancerCenter @icmlf @SaadMSabbagh @JAMANetworkOpen @Cancer_CCFla @CleveClinicFL